Tarannum Mubin, Ding Xizhong, Barisa Marta, Hu Sabrina, Anderson John, Romee Rizwan, Zhang Jin
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA.
Center for Stem Cell and Regenerative Medicine, Department of Basic Medical Sciences, and Bone Marrow Transplantation Center of the First Affiliated Hospital, and Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China.
Nat Biotechnol. 2025 Apr;43(4):516-533. doi: 10.1038/s41587-025-02629-5. Epub 2025 Apr 14.
Innate immune cells, including natural killer cells, macrophages and γδ T cells, are gaining prominence as promising candidates for cancer immunotherapy. Unlike conventional T cells, these cells possess attributes such as inherent antitumor activity, rapid immune responses, favorable safety profiles and the ability to target diverse malignancies without requiring prior antigen sensitization. In this Review, we examine the engineering strategies used to enhance their anticancer potential. We discuss challenges associated with each cell type and summarize insights from preclinical and clinical work. We propose strategies to address existing barriers, providing a perspective on the advancement of innate immune engineering as a powerful modality in anticancer treatment.
包括自然杀伤细胞、巨噬细胞和γδT细胞在内的先天免疫细胞，正作为癌症免疫治疗的有前景候选者而日益受到关注。与传统T细胞不同，这些细胞具有固有抗肿瘤活性、快速免疫反应、良好的安全性以及无需预先抗原致敏就能靶向多种恶性肿瘤的能力等特性。在本综述中，我们研究了用于增强其抗癌潜力的工程策略。我们讨论了与每种细胞类型相关的挑战，并总结了临床前和临床研究的见解。我们提出了解决现有障碍的策略，为先天免疫工程作为抗癌治疗的一种强大方式的进展提供了一个视角。
